Purpose: Persistent pain after breast cancer treatment (PPBCT) affects 25% to 60% of breast cancer survivors and is recognized as a clinical problem, with 10% to 15% reporting moderate to severe pain several years after treatment.
Evidence from randomized clinical trials supports the use of tamoxifen, raloxifene, exemestane, and anastrozole for the reduction of risk of invasive breast cancer, predominately estrogen receptor-positive tumors.
Join Kathleen Horst, MD and Melinda Telli, MD as they present their multidisciplinary expertise on a range of cases pertaining to locally advanced disease breast cancer.
As the complexity and importance of screening, testing, and individualized treatment strategies for breast cancer have increased, so has clinicians’ reliance on the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines and NCCN’s educational interventions to increase knowledge and
As the complexity and importance of screening, testing, and individualized treatment strategies for breast cancer have increased, so has clinicians’ reliance on the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines and NCCN’s educational interventions to increase knowledge and
As the complexity and importance of screening, testing, and individualized treatment strategies for breast cancer have increased, so has clinicians’ reliance on the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines and NCCN’s educational interventions to increase knowledge and
Facebook
X
LinkedIn
Forward